Cargando…
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
OBJECTIVE: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules tha...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361700/ https://www.ncbi.nlm.nih.gov/pubmed/28344818 http://dx.doi.org/10.1186/s40661-017-0045-x |